Evenamide for Negative Symptoms in Schizophrenia - Moves on to Phase 3 Clinical Trials

[twinklestars]

Yes, that’s right. From the previous studies the reduction in the PANSS was modest but broad, 75% of study patients received some benefit.

They said in a recent release though that it had the most effect in people under 32 with 10 or fewer years of illness.

They’re trying it for TRS as well, I don’t know / remember if it was going to be a standalone for that.

ETA here’s the other update from last month.

Evenamide update/orphan drug application, TRS

I don’t know how to attach a pdf, but Newron recently (Sept) updated their page with a pdf report to shareholders that they are going for orphan drug designation with Evenamide in treatment resistant schizophrenia. They expect an answer from the FDA in the first quarter of 2018. They are also planning 2 studies in the EU of 6 and 8 weeks, one in clozapine resistant patients and one in patients experiencing worsening symptoms on antipsychotics they previously responded to. They expect a response for their trial designs from regulators in Nov. The trials are expected to run for 18 months. They are estimating that the phase 2b/3 trials will begin in 2019. It’s the corporate presentation 201…